Developing 31-phosphorus magnetic resonance spectroscopy (31P-MRS) as an imaging biomarker to identify mitochondrial dysfunction in Parkinson’s disease
Objective: To determine if 31P-MRS can identify mitochondrial dysfunction in-vivo and if this correlates with in-vitro measures of mitochondrial function obtained from patient derived fibroblasts…Brain MRI morphological changes in different self-reported sleep disturbances in PD patients
Objective: Our study explored associations between a variety of sleep-related problems and grey matter alterations in PD. Background: Sleep disturbance is a common non-motor feature…Brain MRI Cortical Atrophy correlation to clinical onset in Huntington’s Disease
Objective: To describe brain Magnetic Resonance Imaging (MRI) characteristics in Latin American individuals with Huntington's Disease (HD) and to correlate them to major symptom at…Cortical microstructural alterations are more sensitive than morphology changes to cortical degeneration in Parkinson’s disease with mild cognitive impairment
Objective: To compare the sensitivity of detection cortical degenerative changes in patients with Parkinson’s disease (PD) and mild cognitive impairment (MCI) between the diffusion magnetic…Resting state functional connectivity networks related to MDS-UPDRS motor outcomes in Parkinson’s Disease
Objective: Investigate the functional connectivity network pairs associated with the motor symptoms in people with Parkinson’s disease (pwPD). Background: PD is a neurodegenerative disorder primarily…Total cerebral small vessel score associated with Hoehn and Yahr stages in Parkinson’s disease
Objective: To evaluate the total cerebral small vessel disease (CSVD) score in patients with Parkinson’s disease at different stages and its related factors. Background: Parkinson’s…Evolving inclusion criteria in early manifest Huntington’s disease (HD) to address striatal atrophy: Lessons from HD-GeneTRX-1, the first gene therapy trial
Objective: To describe the early screening experience and evidence-based adaptations to the inclusion criteria for HD-GeneTRX-1 (NCT04120493). Background: AMT-130 is an AAV5-based gene therapy intended…EVALUATION OF THE ABSENCE OF NIGROSOME 1 BY MAGNETIC RESONANCE 3 TESLA IN PARKINSON’S DISEASE ACCORDING TO TIME OF EVOLUTION TO DIAGNOSIS VS MESENCEPHALIC ECOGRAPHY.
Objective: The primary objective was to evaluate the absence of nigrosome 1 in 3TMRI in a group of patients with PD according to their evolutionary…Cognition-related functional topographies in Parkinson’s disease: Localized loss of the ventral default mode network
Objective: We sought to determine whether functional network abnormalities seen in patients with Parkinson’s disease (PD) and cognitive decline reflect the loss of the default…Expanding the phenotypic spectrum of diabetic striatopathy: a case series
Objective: To illustrate the spectrum of diabetic striatopathy by presenting 3 cases with different clinical and neuroimaging findings. Background: Diabetic striatopathy is a rare complication…
- « Previous Page
- 1
- …
- 26
- 27
- 28
- 29
- 30
- …
- 72
- Next Page »